Decision Resources’ European Physician & Payer Forum report “Drug-Resistant Gram-Negative Infections: How Will the Threat of Multidrug-Resistant Gram-Negative Pathogens Impact Market Access for Current and Emerging Antibiotics in the EU5?” explores the many clinical and funding/budgetary/reimbursement factors that affect the use and sales of antibacterial agents targeting gram-negative pathogens. It draws insights from 250 surveyed infectious disease specialists or internal medicine physicians in the EU5 and from interviews with 15 European payers, to explore how emergent pathogen drug resistance will affect sales of premium-priced branded agents for hospital-based treatment of gram-negative infections and to examine levers and barriers that will promote or restrict market access for key emerging therapies. Interviewed payers, all of whom have influence at a national or regional level, include the following:
- France: A past member of the Transparency Commission (CT) who advises the High Authority for Health (HAS) on market access, pricing, and reimbursement. Hospital Pharmacy Directors.
- Germany: Key opinion leader with expertise in quality assurance, quality management, drug budget guidance, managed care, and disease management. Provides medical guidance to the Joint Federal Committee of Physicians, Dentists, Hospitals, and Health Insurance Funds (GBA) as a trained physician. A Pharmacy Director of a large university hospital.
- Italy: A regional hospital formulary (PTOR) member with responsibility for assessing new drugs for formulary inclusion, and a hospital formulary (PTO) co-chair with responsibility in the drug evaluation and tendering process. Regional payers and Chief Pharmacists.
- Spain: Consultant for the Ministry of Health, and hospital pharmacy committee member. Hospital Pharmacy Director. Regional Formulary Committee member.
- United Kingdom: Hospital Program Director who sits on the local NHS commissioning board and on National Institute for Health and Care Excellence (NICE) technology appraisal committees. Head Pharmacist and formulary committee member. PCT Head of Medicines Management with responsibility for commissioning for drugs in primary and secondary care.